Literature DB >> 23860726

Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer.

Y Homma1, K Taniguchi, M Nakazawa, R Matsuyama, R Mori, K Takeda, Y Ichikawa, K Tanaka, I Endo.   

Abstract

PURPOSE: Regulatory T cells (Tregs) play a role in the immunosuppressive state in pancreatic cancer patients. We aimed to evaluate the changes of immune cells population including Tregs caused by gemcitabine (GEM)-based chemotherapy.
METHODS: Fifty-three patients with pancreatic cancer were enrolled in this study, of which 32 received GEM- based chemotherapy. Blood samples were collected before and at least 2 weeks after the last dose of chemotherapy. The peripheral blood mononuclear cells (PBMCs) were subjected to flow cytometry analysis after labeling with anti-CD4, anti-CD25, and anti-Foxp3 antibodies. Other lymphocytes and NK cell markers were also measured. The proliferative capacity of PBMCs stimulated with anti-CD3 was analyzed using H(3) thymidine.
RESULTS: The percentage and number of Tregs were significantly decreased after chemotherapy (p = 0.032, p = 0.003, respectively). The other immune cells and the proliferative capacity did not change.
CONCLUSION: This study showed that GEM-based chemotherapy produced an immunomodulatory effect via the depletion of Tregs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23860726     DOI: 10.1007/s12094-013-1079-0

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  29 in total

1.  Clinical roles of increased populations of Foxp3+CD4+ T cells in peripheral blood from advanced pancreatic cancer patients.

Authors:  Tetsuya Ikemoto; Takeshi Yamaguchi; Yuji Morine; Satoru Imura; Yuji Soejima; Masahiko Fujii; Yoichi Maekawa; Koji Yasutomo; Mitsuo Shimada
Journal:  Pancreas       Date:  2006-11       Impact factor: 3.327

2.  Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).

Authors:  Masato Ozaka; Yuji Matsumura; Hiroshi Ishii; Yasushi Omuro; Takao Itoi; Hisatsugu Mouri; Keiji Hanada; Yasutoshi Kimura; Iruru Maetani; Yoshinobu Okabe; Masaji Tani; Takaaki Ikeda; Susumu Hijioka; Ryouhei Watanabe; Shinya Ohoka; Yuki Hirose; Masafumi Suyama; Naoto Egawa; Atsushi Sofuni; Takaaki Ikari; Toshifusa Nakajima
Journal:  Cancer Chemother Pharmacol       Date:  2012-01-17       Impact factor: 3.333

Review 3.  Surgery for pancreatic cancer: recent controversies and current practice.

Authors:  Curtis J Wray; Syed A Ahmad; Jeffrey B Matthews; Andrew M Lowy
Journal:  Gastroenterology       Date:  2005-05       Impact factor: 22.682

4.  Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells.

Authors:  Lorna Rettig; Samuel Seidenberg; Iana Parvanova; Panagiotis Samaras; Alessandra Curioni; Alexander Knuth; Steve Pascolo
Journal:  Int J Cancer       Date:  2011-01-07       Impact factor: 7.396

5.  Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy.

Authors:  Anna K Nowak; Bruce W S Robinson; Richard A Lake
Journal:  Cancer Res       Date:  2002-04-15       Impact factor: 12.701

6.  Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.

Authors:  Nobuyoshi Hiraoka; Kaoru Onozato; Tomoo Kosuge; Setsuo Hirohashi
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

Review 7.  Chemotherapy and tumor immunity: an unexpected collaboration.

Authors:  Leisha A Emens
Journal:  Front Biosci       Date:  2008-01-01

Review 8.  Tregs and rethinking cancer immunotherapy.

Authors:  Tyler J Curiel
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

9.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

10.  Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer.

Authors:  Junko Yokokawa; Vittore Cereda; Cinzia Remondo; James L Gulley; Philip M Arlen; Jeffrey Schlom; Kwong Y Tsang
Journal:  Clin Cancer Res       Date:  2008-02-15       Impact factor: 12.531

View more
  36 in total

1.  p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.

Authors:  Nicola R Hardwick; Paul Frankel; Christopher Ruel; Julie Kilpatrick; Weimin Tsai; Ferdynand Kos; Teodora Kaltcheva; Lucille Leong; Robert Morgan; Vincent Chung; Raechelle Tinsley; Melissa Eng; Sharon Wilczynski; Joshua D I Ellenhorn; Don J Diamond; Mihaela Cristea
Journal:  Clin Cancer Res       Date:  2018-01-04       Impact factor: 12.531

2.  Overcoming immunosuppression to enhance a p53MVA vaccine.

Authors:  Nicola Hardwick; Vincent Chung; Mihaela Cristea; Joshua DI Ellenhorn; Don J Diamond
Journal:  Oncoimmunology       Date:  2014-12-15       Impact factor: 8.110

Review 3.  Conditioning neoadjuvant therapies for improved immunotherapy of cancer.

Authors:  Zachary Benson; Saeed H Manjili; Mehran Habibi; Georgi Guruli; Amir A Toor; Kyle K Payne; Masoud H Manjili
Journal:  Biochem Pharmacol       Date:  2017-08-10       Impact factor: 5.858

Review 4.  Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.

Authors:  Hua Zheng; Masha Zeltsman; Marjorie G Zauderer; Takashi Eguchi; Raj G Vaghjiani; Prasad S Adusumilli
Journal:  Immunotherapy       Date:  2017-09       Impact factor: 4.196

Review 5.  Strategies for Increasing Pancreatic Tumor Immunogenicity.

Authors:  Burles A Johnson; Mark Yarchoan; Valerie Lee; Daniel A Laheru; Elizabeth M Jaffee
Journal:  Clin Cancer Res       Date:  2017-04-01       Impact factor: 12.531

6.  Intratumoral T cell depletion following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer is associated with poor clinical outcome.

Authors:  Shabaz Sultan; Mark A J Gorris; I Jolanda M de Vries; Niven Mehra; Sandra van Wilpe; Diederik M Somford; Heidi V N Kusters-Vandevelde; Rutger H T Koornstra; Winald R Gerritsen; Michiel Simons; Antoine G van der Heijden
Journal:  Cancer Immunol Immunother       Date:  2022-06-30       Impact factor: 6.968

7.  Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection.

Authors:  Hirokazu Kubo; Takashi Murakami; Ryusei Matsuyama; Yasuhiro Yabushita; Nobuhiro Tsuchiya; Yu Sawada; Yuki Homma; Takafumi Kumamoto; Itaru Endo
Journal:  World J Surg       Date:  2019-12       Impact factor: 3.352

8.  Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence.

Authors:  David W Dawson; Martin E Fernandez-Zapico
Journal:  Gastroenterology       Date:  2016-06-29       Impact factor: 22.682

Review 9.  The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications.

Authors:  Ryota Tamura; Toshihide Tanaka; Yasuharu Akasaki; Yuichi Murayama; Kazunari Yoshida; Hikaru Sasaki
Journal:  Med Oncol       Date:  2019-11-11       Impact factor: 3.064

10.  89Zr-Labeled Anti-PD-L1 Antibody PET Monitors Gemcitabine Therapy-Induced Modulation of Tumor PD-L1 Expression.

Authors:  Kyung-Ho Jung; Jin Won Park; Jin Hee Lee; Seung Hwan Moon; Young Seok Cho; Kyung-Han Lee
Journal:  J Nucl Med       Date:  2020-09-11       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.